A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

Paller, A.S., Siegfried, E.C., Simpson, E.L. et al. (12 more authors) (2021) A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Journal of the European Academy of Dermatology and Venereology, 35 (2). pp. 464-475. ISSN 0926-9959

Abstract

Metadata

Authors/Creators:
  • Paller, A.S.
  • Siegfried, E.C.
  • Simpson, E.L.
  • Cork, M.J. ORCID logo https://orcid.org/0000-0003-4428-2428
  • Lockshin, B.
  • Kosloski, M.P.
  • Kamal, M.A.
  • Davis, J.D.
  • Sun, X.
  • Pirozzi, G.
  • Graham, N.M.H.
  • Gadkari, A.
  • Eckert, L.
  • Ruddy, M.
  • Bansal, A.
Copyright, Publisher and Additional Information: © 2020 Regeneron Pharmaceuticals, Inc. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Dates:
  • Accepted: 21 August 2020
  • Published (online): 8 November 2020
  • Published: February 2021
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 16 Aug 2021 13:07
Last Modified: 16 Aug 2021 13:07
Status: Published
Publisher: Wiley
Refereed: Yes
Identification Number: https://doi.org/10.1111/jdv.16928
Related URLs:

Download

Filename: jdv.16928.pdf

Licence: CC-BY-NC-ND 4.0

Share / Export

Statistics